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Abstract
Cystic fibrosis (CF) is one of the most common indications for lung transplant 
(LTx) and nearly one-third of the LTx worldwide are performed in people with CF 
(PwCF). Due to vast developments in diagnostic modalities, antibiotic therapies, 
and management of associated comorbidities in dedicated and experienced centres, 
over the past few decades, more PwCF are reaching adulthood than ever before. 
This has increased the burden on transplant programs particularly in a universal 
donor shortage scenario. To improve the donor pool a diligent and proactive donor 
care management, acceptance of marginal organs and utilisation of ex-vivo lung 
perfusion systems for organ preservation, assessment, and improvement is being 
advocated widely. LTx is not a readily available therapy and the average waiting 
time is 18 months in the UK. Therefore, it is essential that PwCF are referred for 
LTx assessment when their disease is stable, before respiratory deterioration leads 
to overall deconditioning of the patients. Once listed for LTx, it is crucial to control 
waiting list mortality by prioritising rapidly deteriorating patients through schemes 
like the lung allocation score, national urgent and super-urgent waiting lists, and 
institutional highlighting of deteriorating patients that do not meet other urgent 
criteria. LTx in PwCF is challenging due to colonisation of the respiratory tract with 
multi-drug resistant organisms, associated comorbidities such as diabetes, liver dis-
ease, gastro-oesophageal reflux, and distal intestinal obstruction syndrome (DIOS) 
and CF-specific technical difficulties (adhesions due to prior pneumothoraces or 
pleurodesis, or bronchial collaterals that increase surgical time). Hilar lymphade-
nopathy and bronchial collaterals may increase surgical time, organ ischemia time, 
intra and post-operative bleeding, and blood transfusions. Advances in immuno-
suppression, prophylactic anti-viral and anti-fungal therapies, early ambulation 
and rigorous physiotherapy, and meticulous postoperative follow up with spirom-
etry, x-rays, and bronchoscopies to detect rejection at the early stage followed by 
its efficient treatment have helped to improve post-LTx survival in the CF patients. 
Constant development in the surgical field with adoption of off-pump transplanta-
tion, sternal sparing bilateral thoracotomy approach, and utilisation of mechanical 
circulatory assist as a bridge to transplant and as a support for primary graft failure 
strives for better outcomes. However, chronic lung allograft dysfunction, chronic 
refractory infections, malignancies, and CF associated comorbidities remain major 
determinants of post-LTx long term survival. Despite this, CF patients are often 
good candidates for re-do LTx with improving survival outcomes. In this chapter, 
we are compiling the different aspects of LTx in PwCF emphasising the advances 
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in bridge to transplantation, the surgical approach, management of primary graft 
failure, and immunosuppression as well as complications post-transplant.
Keywords: cystic fibrosis, lung transplantation, advances,  
minimally invasive lung transplantation, off pump lung transplantation
1. Introduction
While it took years following the first human LTx in 1963 for this procedure to 
become a gold standard therapy in the management of end-stage lung disease, the 
procedure took off in the 80s following the introduction of Cyclosporin in medi-
cal practice. The first transplant in a patient with CF was a heart-lung transplant 
performed by Magdi Yacoub in Harefield Hospital in the United Kingdom [1]. Since 
then, nearly ten thousand patients with CF have undergone LTx worldwide [2]. 
According to the 36th adult lung and heart-lung transplant report comprising more 
than 69000 adult LTx in the ISHLT registry, 15.2% of all adult LTx were performed 
in PwCF [2]. Although the number of transplants performed for each indication 
has increased ever since, the proportion of patients transplanted for CF continues 
to fall, now accounting for 13% of total adult lung transplants, compared with over 
15% five years ago [2, 3]. With constant improvement in knowledge, better manage-
ment of infective exacerbations, developments in the field of antimicrobials and 
breakthrough modulator therapy for PwCF, survival has improved in CF patients 
significantly [4–6]. However, this may have led not only to increasing numbers of 
PwCF meeting criteria for LTx but unfortunately, also to delayed referrals, refer-
ral of sicker patients with comorbidities, and patients with complex colonisations 
of multi-drug resistant organisms. Despite this, with 9.9 years of median survival 
and 12.4 years of conditional survival in patients that survive beyond the first year, 
PwCF demonstrate the best survival compared to any other indication for LTx 
[2]. Moreover, survival in ISHLT registry (1992 to 2017) stratified in 3 eras show a 
significant improvement in the survival of PwCF in the recent era when compared 
with other indications for LTx [2]. This is mainly due to the younger age and good 
other end-organ function of these patients at the time of transplantation. On the 
other hand, CF patients when compared to other indications for LTx pose a set of 
exclusive challenges. Familiarity, experience and expertise of the transplant team to 
deal with these problems make a significant difference in the outcomes.
2. Patient selection
2.1 Indications and contraindications of LTx in CF
With a scarcity of donor organs and higher mortality in LTx recipients compared 
to other organs, health economics would support offering a limited supply of donor 
organs to recipients expected to benefit the most. However, the onus to identify such 
recipients falls upon timely referral and listing of the candidates for potential LTx. A 
clinical window where the patient is symptomatic enough to require LTx but strong 
enough to survive the operative trauma varies with the individual patient. Generally, 
when the FEV1 in PwCF drops below 30%, their expected median survival is around 
2 years [7]. However, FEV1 is not a reliable indicator of survival as many with CF 
with longstanding low lung function may survive without transplantation. Currently 
though, in the absence of a better option, it remains the best available indicator 
for referral and listing purposes. Inadequacy of clinical parameters to sufficiently 
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predict survival in CF patients raise a need for mortality prediction models. One 
of the first such comprehensive models recognised age, respiratory microbiology, 
height, FEV1, annual number of hospital admissions and courses of home intrave-
nous antibiotics as the most important predictors of 2-year mortality [8]. However, 
the authors also admit that their model is no better than the widely used FEV1 < 30% 
predicted. Thus, referral of patients for transplant based either on their model prob-
ability of dying within 2 years or on an FEV1 of less than 30% predicted could result 
in a high rate of premature referral, as a substantial proportion of patients predicted 
to die within 2 years based on these criteria would survive this period. Therefore, 
it is wise to take into consideration risk factors associated with early mortality in 
PwCF when shortlisting them for LTx. One of the biggest CF databases, the UK CF 
Registry reviewed records from 2005 to 2015 on 6181 individuals, and acknowledged 
strong associations of Burkholderia cepacia infection, CF-related diabetes, and 
more hospital days on IV antibiotics with decreasing survival [9]. A Canadian CF 
registry analysis identified older age at diagnosis, diabetes, and deteriorating FEV1 
as predictors of reduced survival [10] whilst a recent meta-analysis based upon 11 
studies identified Burkholderia cenocepacia and ascending chronological year of LTx 
as predictors of post-LTx mortality [11]. Referring physicians whilst focusing on the 
FEV1, should also pay special attention to these risk factors for poor survival when 
considering referral to a transplant centre.
Contraindications of LTx in the CF are similar to other end-stage lung disease 
causes and are broadly divided into absolute and relative contraindications. A 
consensus document for the selection of LTx candidates offers a thorough review 
into the contraindications for LTx (Table 1) [12].
2.2 Criteria for referral and listing
Early or sometimes premature referral of PwCF to transplant centres offers 
patients a chance of early transplant assessment to maximise their window of 
opportunity for donor offers and a LTx. Additionally, early referral has the potential 
to identify modifiable contraindications to LTx or risk factors of transplant mortal-
ity allowing these to be treated and optimised before requiring listing. A delayed 
referral carries a risk of insufficient time to wait and less number of donor offers 
to the referred patients. Candidates may miss their window of opportunity and be 
removed from the waiting list due to clinical deterioration or worse. An ideal time 
of listing any candidate for LTx is when the benefits from the procedure balance 
its risk. It is not unusual practice at transplant centres to send patients back to the 
referring physicians for not meeting the criteria of listing post-assessment but iden-
tifying them as future candidates. A 2006 ISHLT update for selection of transplant 
candidates for the first time separated referral and listing criteria emphasising a 
timely referral of the end-stage lung disease candidate to transplantation centres 
[13]. These were revised in a 2014 update as summarised in Table 2 [14].
2.3 Pre-operative work-up
Transplant teams while assessing referred CF patients for LTx should ask two 
vital questions- (i) Is a transplant required- in other words, is the transplant going 
to improve survival and quality of life? (ii) Is the patient transplantable? – i.e. is the 
patient going to survive the transplant?
Transplant evaluation requires a medical assessment, psychological assessment, and 
in some countries, financial assessment. The medical assessment requires an admission 
for 2–3 days so that a patient can have multiple investigations and be reviewed by the 
multi-disciplinary team (MDT) (Table 3) [15]. Additional investigations that may be 
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required include CT coronary angiogram (CTCA) in PwCF aged over 40 years or right 
heart catheterisation in severe pulmonary hypertension. All referrals require a dental 
assessment before listing, but PwCF may require assessment by ENT or gastroenterol-
ogy doctors in addition. Psychology, palliative care and physiotherapy review during 
their assessment provides insight on a patient’s suitability to undergo transplantation, 
and social support is also explored during this time. In some countries, financial evalu-
ation is necessary to ensure a potential recipient can afford the immediate transplant 
care, lifelong aftercare and medications, and management of complications. Following 
this period of assessment, patients are subsequently discussed at MDT meetings, which 
include respiratory physicians, transplant surgeons, psychologists, immunologists, 
radiologists, dietitans and physiotherapists. After discussion, outcomes for each patient 
Absolute contraindications
History of malignancy with less than 5 years of disease free interval
Untreatable significant dysfunction of another major organ system
Coronary artery disease not amenable to revascularization
Acute medical instability (sepsis, myocardial infarction, liver failure)
Uncorrectable bleeding diathesis
Chronic infection with highly virulent and/or resistant microbes
Evidence of active Mycobacterium tuberculosis infection
Significant chest wall or spinal deformity
BMI ≥ 35.0 kg/m2
Current or history of non-adherence to medical therapy
Psychologic conditions with inability to cooperate with medical team
Absence of adequate or reliable social support system
Severely limited functional status with poor rehabilitation potential
Substance abuse or dependence
Relative contraindications
Age > 65 years in association with low physiologic reserve
BMI 30.0–34.9 kg/m2
Progressive or severe malnutrition
Severe, symptomatic osteoporosis
Extensive prior chest surgery with lung resection
Mechanical ventilation and/or extracorporeal life support
Colonisation/infection with highly resistant or virulent organisms
Infection with hepatitis B and/or C
Infection with HIV
Infection with Burkholderia cenocepacia, Burkholderia gladioli
Infection with multi-drug–resistant Mycobacterium abscessus
Atherosclerotic disease burden
Diabetes mellitus, systemic hypertension, epilepsy
Central venous obstruction, peptic ulcer disease, gastroesophageal reflux
Table 1. 
Absolute and relative contraindications for LTx in CF.
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include decision for active listing, further information required, rejection as unsuitable, 
or deferral as too well.
2.4 Waiting list
The time spent by potential recipients on the LTx waiting list depends on various 
factors including blood group, HLA antibody status and the size of pleural cavities. 
Whilst on the waiting list, patients are encouraged to exercise regularly, achieve or 
maintain a healthy BMI, avoid frequent infective exacerbations, and inform any 
changes in circumstances urgently. Transplant coordinators maintain contact with 
patients on the waiting list, update records, educate patients and communicate 
between all members of the transplant team. Traditionally, organ offering systems 
take into account time spent on the waiting list and the clinical status of the can-
didates, but influenced by the urgency of transplantation. With this freedom of 
recipient selection to the transplant centres, fairness in the distribution of the donor 
organs to the most worthy recipients may be jeopardised. A study looking into 2213 
lung-only registrations into the UK Transplant Registry between 2004 and 2014 
showed discrepancies between the risk profile and probability of LTx. The chance 
of LTx after listing differed by the combined effect of disease category and centre, 
height (taller patients having a greater chance of transplant) and blood group 
(blood group ‘O’ having highest waiting mortality) [16].
The ideal recipient for any donor organ is the one with urgent need of trans-
plantation along with the longest expected post-transplant survival. The Lung 
Allocation Score (LAS) system adopted in the US in 2005 incorporated estimated 
survival benefit offered by LTx by 1 year after surgery and medical urgency. Since 
its introduction, the number of deaths on the waiting list in the US has reduced 
Timing of referral
FEV1 < 30% pred or falling rapidly despite optimal therapy
A 6-minute walk distance <400 m
Pulmonary hypertension in absence of hypoxic exacerbation
Clinical decline- increasing exacerbations with -
(i) Acute resp. failure requiring NIV
(ii) Increasing antibiotic resistance and poor clinical recovery from exacerbations
(iii) Worsening nutritional status despite supplementation
(iv) Pneumothorax
(v) Life threatening hemoptysis despite bronchial embolization
Timing of listing
Chronic respiratory failure with hypoxia alone (PaO2 < 8 kPa)




Rapid lung function decline
WHO Functional Class IV
Table 2. 
Timing of referral and timing of listing for LTx in CF patients.
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from 500/year to 300/year, the distribution of recipients has changed, and the 
number of LTx increased despite no substantial increase in organ donors with no 
decrease in 1-year survival after LTx, even though sicker patients were undergoing 
transplant [17]. With the introduction of the LAS, the number of LTx for PwCF 
Blood tests
Full blood count, Coagulation studies, Blood glucose, Blood group
Kidney function, Liver function
Lipid profile, Thyroid function
HLA status, Panel reactive antibody status
Radiology studies
Chest CT, Sinus CT
Abdominal ultrasound
Functional studies
Lung function: Spirometry, lung volumes and diffusion
Arterial blood gases
6-min walk test
Cardiac: ECG, Echocardiogram, right heart catheterisation
Bone mineral density
Infection screen




Serology for HIV, hepatitis B, hepatitis C
Serology for cytomegalovirus, Ebstein-Barr virus, Varicella zoster






Faecal occult blood screening
Autoimmune screen
ANA, ENA, DNA antibody, Rheumatoid factor, ANCA, Immunoglobulins
Creatine kinase
Compliance screen Serum cotinine
Consultant referrals




Assessment for LTx in CF patients.
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increased by 25%, 70% of CF patients were transplanted within 1 year of being 
listed, and 1-year waiting-list mortality decreased from 15–10% [18]. The LAS was 
then adopted by Eurotransplant who distribute lungs between donor countries 
if they cannot be used within the donor’s country of origin. After 3 years, the US 
results were imitated in Germany [19]. However, some reports have shown that 
the LAS increases the complexity of the post-transplant course and postoperative 
mortality [20, 21] and in some cases, reduced survival outcomes irrespective of 
risk profile [22]. Current allocation policy in the US initially utilises donor organ 
location and age to match with compatible wait-listed patients, followed by the LAS 
value, ABO blood type, thoracic cavity size and immunological compatibilities to 
ultimately select a match.
In the UK, between 2004 and 2014, 79.2% of patients with chronic obstruc-
tive pulmonary disease (COPD) received a transplant by 3 years of wait on the 
list versus 61.3% of PwCF and 48.9% of those with pulmonary fibrosis (PF). 
During the same period, patients with COPD had the lowest mortality on the list. 
In comparison, PwCF had a 230% higher chance of death on the list without LTx 
[16]. To optimise this disparity in organ allocation, in May 2017 the Cardiothoracic 
Advisory Group introduced an urgent and super-urgent lung allocation scheme in 
which patients at high risk of death without a LTx are prioritised at a national level 
[23]. In this scheme, patients supported with ECMO (extracorporeal membrane 
oxygenation) or iLA (interventional lung assist) as a bridge to transplant are 
prioritised on a national super-urgent waiting list, whilst severely unwell patients 
particularly in CF patient, worsening hypoxia and hypercapnia, persistently low 
pH, refractory right heart failure and ongoing massive hemoptysis can be recom-
mended for the national urgent waiting list. Other policies in the UK include small 
adults (≥16 years of age and ≤ 155 cm of height) receiving offers of lungs from 
paediatric donors before other adults, (but after paediatric patients,) and priority 
is given to blood group identical recipients over blood group compatible recipients. 
In some cases, ‘zonal centre’ priority is given to patients at a centre if the donor 
is located within that centre’s allocation zone [23]. However, the current system 
remain inefficient in prioritising patients depending upon the type of lung disease, 
and building individual risk profiles combining the factors such as urgency, height, 
and blood group. All current organ allocation systems strive to achieve the best 
post-transplant survival rates whilst reducing waiting list mortality, but remain far 
from ideal. Current systems should continue to undergo periodic evaluations, adopt 
practices from other systems, and remain dynamic to outcome-driven changes. The 




Availability of donor organs remains the most important limiting factor 
for transplantation as lungs, in particular, have the lowest harvest rate. The 
Eurotransplant registry reports utilisation of lungs from only 698 donors out of 
1192 registrants in the year 2019 which is significantly lower compared to abdomi-
nal organs [24]. Significant progress has been made in the last decade to improve 
the donor pool for lungs, but there remains a huge scope for further development. 
Donation after circulatory death (DCD) is becoming commonplace with a recent 
review of ISHLT data showing comparable five-year survival in recipients receiv-
ing lungs from donors after brain death (DBD) against DCD (63% vs. 61%) [25]. 
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Metanalyses comparing LTx outcomes dependent on the type of donation have 
shown no difference in survival, primary graft dysfunction (PGD) or acute rejec-
tion [26, 27]. Protocol-based management of multiorgan brain dead donors with a 
focus on lung donation in recent years have significantly improved lung utilisation 
rates [28]. A ventilation strategy with a low tidal volume and higher PEEP, along 
with a neutral or negative fluid balance helps protect potential donor lungs [29].
Standard lung donor criteria have been liberalised in the last two decades with 
an increasing proportion of marginal donor lungs being utilised for LTx with 
equivalent outcomes. A review of the UNOS database showed reduced 1-year sur-
vival with the use of marginal donor lungs, especially in high-risk recipients [30]; 
however, the survival of these patients on the waiting list without transplantation 
is questionable. Moreover, it’s the high-risk recipients and not marginal donors that 
are associated with poor outcomes [31]. A lung donor score (LDS) based upon past 
medical history, smoking history, age, arterial blood gases, chest X-ray, and bron-
choscopy findings, that accurately predicts the likelihood of organ acceptance and 
recipient mortality may facilitate donor risk assessment and patient selection [32]. 
Ex-vivo lung perfusion (EVLP) is now an established therapy to repair and evalu-
ate marginal lungs for transplantation with comparable post-transplant outcomes 
[33–35].
To expand the donor pool, more countries are embracing an ‘opt-out’ system 
for organ donation. In Europe, the 2018 figures of lung donor utilisation rate were 
significantly higher in Austria and Belgium (9.8 and 10.8 ppm) where they have 
opt-out systems for organ donation, compared to Germany and the Netherlands 
(3.8 and 4.7 ppm) where an opt-in system remains [36]. The waiting list mortality 
rates in countries with high donation rates are lower compared to those in countries 
with low donation rates (7% vs. 12% at 1 year), with higher quality donor lungs 
more often used in these countries with high donation rates, thus offering a chance 
of better outcomes in recipients [37].
3.2 Challenges in LTx for CF
3.2.1 Preoperative procedures
The average annual incidence of pneumothorax in PwCF is 1:167 patients per 
year and 3.4% of CF patients will experience a pneumothorax during their lifetime 
[38]. According to current CF Foundation practice guidelines, a chest drain is 
recommended for large pneumothoraces or small pneumothoraces with clinical 
instability, whilst surgical pleurodesis is recommended for recurrent, large pneu-
mothoraces [39]. The incidence of CF patients with a history of pleural intervention 
undergoing LTx is increasing as patients are being offered alternative interventional 
therapies before resorting to LTx.
The inflammatory/chronic infective component of CF independently contrib-
utes to increased pleural adhesions [40]. Dense pleural adhesions encountered 
during LTx in such patients increases surgical time, bleeding, blood transfusion 
requirement (that may further increase the chance of primary graft failure (PGD)), 
renal injury, prolonged respiratory wean and early mortality [41, 42]. Some groups, 
however, report no difference in operative outcomes despite pleural adhesions in 
PwCF [40, 43, 44]. It is worth noting that the LAS nor the ISHLT Registry consider 
previous cardiothoracic procedures as a contraindication to LTx.
In a multicentre study of CT scan scoring in PwCF based on infection/inflam-
mation, air trapping/hypoperfusion, normal/hyperperfusion, and bulla/cysts, 
infection/inflammation was found to have a significant predictive value for survival 
[45]. Careful and detailed studies of CTs for pleural thickening, irregularity and 
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calcification before listing for LTx is recommended to anticipate operative chal-
lenges and risk stratification. Avoidance of CPB, starting the procedure on the 
side of fewer adhesions, minimising blood loss by meticulous adhesiolysis and the 
presence of an experienced surgeon may prove helpful. PwCF may require lung 
resection for localised severe bronchiectasis, atelectasis, bronchopleural fistula 
refractory to medical management and severe hemoptysis refractory to conserva-
tive management [46, 47]. This not only causes pleural adhesions, but can also lead 
to loss of pleural cavity volume. At LTx evaluation, such patients require strategic 
planning while setting donor size parameters; they may require a donor lung reduc-
tion or lobar lung implantation.
3.2.2 Preop ECMO and mechanical ventilation
It is not uncommon for PwCF to suffer an infective exacerbation causing acute 
hypercapnic respiratory failure with worsening respiratory acidosis. Most exacer-
bations are managed with antibiotics and chest physiotherapy, but some require 
respiratory support with inhaled oxygen or escalation to non-invasive ventilation 
(NIV). Patients with deteriorating gas exchange despite NIV either require endotra-
cheal intubation and invasive mechanical ventilation (IMV) or ECMO despite or to 
minimise IMV. Once an acceptable gas exchange is established with ECMO, sedation 
wean and extubation or tracheostomy should be performed in these patients to 
allow for ongoing physiotherapy rehabilitation.
Recent evidence from the UNOS database comprising 14,320 patients in the 
LAS era showed an association between pre-transplant ECMO and IMV with 
30-day mortality as well as prolonged hospital length of stay after LTx [48, 49]. 
The Extracorporeal Life Support Organisation (ELSO) Registry showed 52% 
survival in CF patients supported on ECMO [50]. Fuehner et al. demonstrated 
improved survival in patients bridged to LTx with an “awake ECMO” strategy when 
compared with those managed with IMV (80% vs. 50% at 6 months), emphasis-
ing the potential advantages of minimising time sedated [51]. The key benefits of 
maintaining patients awake on ECMO is the avoidance of complications associated 
with sedation, intubation, IMV, and immobilisation. They can undertake active 
physiotherapy helping to reduce the rate of muscle wasting and preventing pressure 
sores. Patients are encouraged to eat and drink without enteral feed if possible. 
Meeting family and social media helps to maintain a positive mood, and suboptimal 
therapy or complications can be detected at an earlier stage as patients can identify 
and communicate symptoms of dizziness, breathlessness, and pain [52].
3.3 Procedure of LTx
Despite early success and advantages of heart-lung transplantation for CF 
(fewer anastomoses, shorter ischaemic times and re-utilisation of recipient’s heart 
in a “domino” transplant), it has been superseded by LTx due to donor organ 
shortage and equivalent outcomes [53]. Bilateral sequential LTx in which unilateral 
pneumonectomy and donor lung implantation are performed in sequence is the 
standard operation for a suppurative disease like CF. However, single-LTx after 
synchronous or metachronous contralateral pneumonectomy for PwCF resulting 
in an asymmetric chest and lung volume mismatch may be an acceptable functional 
therapeutic option [54, 55].
The CF patient population consists of a large proportion of children and small 
adults that are not suitable recipients for most adult sized donors leading to an 
increase in the waiting list mortality. For a marginal size mismatch, peripheral lung 
resection, also known as ‘lung shaving’ may suffice, however, donor lung lobectomy 
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to utilise only the upper or lower (preferred option) lobe dependent on the recipient 
pleural cavity size may be required [56, 57]. Bi-partitioning lobar LTx is a bilateral 
lobar transplant from a single donor lung. This can be performed to maximise the 
donor pool, but is not a popular procedure due to technical challenges [58]. Living-
donor lobar LTx (LDLLT) is lifesaving in countries with low cadaveric donation and 
for patients deemed unable to await a cadaveric LTx [59]. Two lobes obtained from 
live donors can adequately support an adult CF patient and the morbidity from 
lobectomy to the healthy donor is minimal. A study where 84% of the cohort were 
CF patients undergoing LDLLT showed a survival of 70% and 45% at 1 and 5 years, 
which is comparable with double-lung cadaveric transplantation according to the 
ISHLT Registry (74% and 49.5% at 1 and 5 years) in in the same year [60].
3.4 Advances in LTx surgery
3.4.1 Minimally invasive LTx
For double LTx in CF, the clamshell is a conventional approach that offers a 
direct vision to the heart and lung hila, but can cause sternal dehiscence, malalign-
ment, wound dehiscence and rarely mediastinitis. These complications are thought 
to be under-reported, but cause significant morbidity through readmissions, mul-
tiple surgical debridements and prolonged wound care. Infection can be difficult to 
treat in the presence of steroid-induced osteoporosis, breathing-induced mobility in 
healing sternal edges, and immunosuppression. Sternal sparing bilateral thoracot-
omy approach may be less painful and may support early extubation, ambulation, 
and rehabilitation [61]. This approach spares the internal mammary arteries, caus-
ing less blood loss, and is superior cosmetically to the clamshell incision. A require-
ment of long instruments and telescopic surgical skills for this approach is a myth. 
Utilisation of a modified rib spreader, with movable and adjustable blades provides 
optimum exposure without injuring the ribs. For emergency conversion to CPB, 
apart from peripheral access via the groin, one can cannulate via the thoracotomy.
3.4.2 Role of mechanical circulatory support in LTx surgery
Double LTx is conventionally performed with the aid of cardio-pulmonary 
bypass. As bilateral sequential LTx became commonplace, the use of CPB during 
the procedure declined. A comparative study of LTx in CF shows that the implanta-
tion of both lungs on CPB after bilateral pneumonectomy and airway decontamina-
tion does offer a protective effect against early graft infection [62]. CBP provides 
complete respiratory support and haemodynamic stability, ease of hilar dissec-
tion and retraction of the heart during the LTx, but can induce an inflammatory 
response, bleeding, (and thus increased requirement of blood transfusions), and 
a higher incidence of PGD [63]. Significantly lower survival was observed in CF 
patients undergoing LTx with the utilisation of extracorporeal circulation [64]. Off-
pump surgery may avoid complications caused by circulatory support but is suscep-
tible to periods of hypotension, hypothermia, and hypoxia. It also exposes the new 
lung to the entire cardiac output potentially causing acute lung injury and PGD.
Off-pump LTx may require emergency conversion to CPB in case of inability to 
tolerate single lung ventilation, hemodynamic instability, or uncontrolled bleeding. 
Off-pump LTx requiring emergent conversion to CPB is by default a part of the on-
pump group in several reports comparing on-pump and off-pump procedures, which 
has found worse outcomes in the on-pump group [65, 66]. In the quest of a fair com-
parison, a further study segregated cases with unplanned CPB conversion and found 
that despite this segregation, patients with comparable preoperative demographic 
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and risk profiles demonstrated better early postoperative outcomes including early 
survival with an off-pump strategy for LTx in comparison to an on-pump strategy. 
While a considerable proportion of high-risk patients require intraoperative conver-
sion from off-pump to CPB with suboptimal outcomes, there is no significant benefit 
to employing an elective on-pump strategy in this high-risk group [67]. Although 
elective use of CPB for LTx has decreased in recent years, mechanical circulatory 
support of some form is still necessary during LTx in the presence of pulmonary 
hypertension, suboptimal cardiac function, severe respiratory disease, and marginal 
donor organs with an insufficient gas exchange when performing one-lung ventila-
tion. Instead of CPB, ECMO that can potentially be continued post-operatively until 
the donor organs recover and pulmonary pressures alleviate is increasingly being 
utilised. ECMO offers cardiopulmonary support without cardiotomy suction, venous 
reservoir, a large amount of prime, and may avoid some complications associated 
with CPB. A meta-analysis of 7 studies comprising 785 patients comparing CPB and 
ECMO in LTx showed a lower rate of primary graft dysfunction, bleeding, renal 
failure requiring dialysis, tracheostomy, intraoperative transfusions, intubation 
time, and hospital stay along with a trend towards lower mortality in the ECMO 
group [68]. Elective use of mechanical circulatory support in LTx for CF is now 
limited to severe secondary pulmonary hypertension or if additional cardiac surgery 
is required, such as atrial septal defect closure. Optimisation with Milrinone and 
nitric oxide before a trial of pulmonary artery clamping can be helpful to assess 
if mechanical support may be required. If there is hemodynamic instability and 
inadequate gas exchange on single lung ventilation, the operation should continue 
under ECMO support, whilst emergency CPB can be ustilised in case of catastrophic 
bleeding, irreversible arrhythmia or hemodynamic instability.
3.4.3 Re-transplantation
CF patients often become candidates for re-transplantation due to their young 
age at the time of their primary transplant. PwCF have overall good post-transplant 
survival but also suffer a higher incidence of bronchiolitis obliterans syndrome 
(BOS). BOS, primary graft failure (PGD) and irreversible airway complica-
tions (stenosis and dehiscence) are the main causes for lung re-transplantation. 
Pseudomonal airway colonisation before and after LTx is thought to be associated 
with the increased prevalence of BOS in CF patients [69]. CF recipients are at 
higher risk of acute cellular rejection and subsequent BOS due to the enhanced 
immune activation associated with CF, their younger age and higher prevalence of 
donor specific antibodies [70, 71]. Scarcity of donor organs and suboptimal out-
comes have always raised doubts about the validity and ethics of re-transplantation, 
especially as historically, the survival post-re-transplantation has remained inferior 
compared to the primary transplantation. Interestingly though, rates of BOS has 
shown an improved trend with 1-year survival increasing from 47% in the 1990s to 
72–78% in the last 15 years [73–75]. Re-transplantation in non-ambulatory, venti-
lated patients, with PGD, anastomotic dehiscence, or less than a year since primary 
transplantation is associated with higher mortality [72–75]. Careful recipient selec-
tion with preoperative optimization in terms of nutrition and functional status, 
along with end-organ function are vital for successful re-transplantation.
4. Complications of LTx in CF
PwCF continue to demonstrate the best survival compared to other indications 
for LTx [76, 77], but suffer the same complications as those without CF to varying 
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extents. Within the first month, primary graft dysfunction, acute infections, and 
technical complications dominate the cause for admissions, transitioning to also 
include rejection in the first year. Rejection and infection remain complicating 
factors throughout a recipient’s life, with malignancy an increasing risk the longer a 
recipient remains on immunosuppression [77, 78].
4.1 PGD
Primary graft dysfunction (PGD) is the main cause of death within the first 
30 days post-operatively [78], and is a form of acute lung injury that involves a 
wide spectrum of signs and symptoms within the first 72 hours of transplanta-
tion. For this reason, it is also known as the “re-implantation response”. PGD is the 
consequence of an inflammatory response triggered by injury to the donor, graft or 
recipient, ischaemia, and reperfusion, and can cause a decrease in oxygenation with 
minimal pulmonary infiltrates caused by oedema, through to complete graft failure 
and death or re-transplantation. PGD is caused by the activation of pulmonary 
macrophages and circulating leukocytes and is divided into two phases – a first 
acute phase of lung schaemia and reperfusion injury, which drives the second phase 
mediated by massive neutrophil recruitment which amplifies the initial innate 
immune reaction.
A number of risk factors for development of PGD have been identified; in gen-
eral, donor factors tend to impact the initial 24 hours post-transplantation, whilst 
the recipient factors affect later outcomes. Donor-related risk factors include sex, 
age, smoking history, ischaemic time, and brain-death-associated lung injury [79, 
80]. Given the underlying pathophysiology of PGD, the approach to management 
is based on the treatment of ARDS (acute respiratory distress syndrome) using 
protective IMV and maintaining a negative fluid balance. However, this treatment 
plan is complicated by patients who may not tolerate permissive hypercapnia 
cardiologically, and fragile renal function due to multiple insults in the operative 
and immediate post-operative period.
It has been shown that lung recipients who develop PGD have a marked graft 
and systemic inflammatory response, and that the timing and grade of PGD sever-
ity has implications to the risk of developing BOS (bronchiolitis obliterans) later 
[81, 82].
4.2 Infections
Post-transplant infections remain a significant source of morbidity and mortal-
ity in all recipients, but this is complicated by the nature of the multi-resistant 
organisms found in CF recipients due to repeated antibiotic courses. It has long 
been accepted that PwCF are chronically colonised with bacteria, and so finding 
positive microbiology in the sputum of transplanted PwCF does not necessitate an 
acute infection, but equally, transplanting the lungs does not eradicate individu-
als with CF of the bacteria which remain colonised in the upper airways and the 
sinuses. PwCF colonised with Mycobacterium abscessus or Bulkholderia cenocepacia 
cannot be transplanted in most centres due to the high morbidity and mortality 
rates associated with these conditions post-transplantation. Though there have been 
some success in transplanting PwCF who have negative sputum for M. abscessus 
pre-transplantation but remain on treatment [83–85].
It is just as important to consider the donor’s microbiological profile. All donors 
are screened for obvious reasons for HIV, hepatitis B and hepatitis C, but where 
donors have died from undiagnosed infections, the risk of transmitting a poten-
tially lethal infection into a recipient has to be considered. In addition, the longer 
13
Lung Transplantation in Patients with Cystic Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.94523
a potential donor is ventilated, the more likely they are to become colonised with 
antibiotic-resistant flora, complicating a future transplant. BAL before harvesting 
or implantation is useful to culture and therefore guide antibiotic management in 
the peri-operative and immediate post-operative period.
Like any major surgery, surgical site infection can also occur. Good peri-operative 
lavages of the donor lungs and the recipient’s pleural cavity is important to reduce 
the presence of infected material. It is often difficult for antibiotics to penetrate the 
pleural cavity so although infections at a wound site are unusual, once present, they 
can be difficult to manage and treat. Again, PwCF are at higher risk of infections at 
anastomotic and surgical sites by the nature of the underlying disease. The antibiot-
ics selected peri-operatively and post-operatively are guided by the patient’s response 
to antibiotic combinations pre-operatively, as well as microbiological sensitivities. 
Just like other intensive-care patients, post-transplant patients are at high risk of 
ventilator-associated pneumonia (VAP), and so unless there are contraindications, it 
is important to work towards extubating the patient as expediently as possible.
CMV (cytomegalovirus) disease used to be a significant concern post-trans-
plant, but the routine use of prophylactic and treatment valgangiclovir combined 
with surveillance management has significantly reduced the risk of infection 
or reactivation [86]. A recent study looking at the incidence of CMV infection 
in heart transplant recipients has estimated the rate of early-onset (<100 days 
post-transplant) CMV disease at only 2%, compared with late-onset (>100 days 
post-transplant) at 7.5%, and this is largely thought to be due to the introduction 
of valganciclovir [87]. EBV (Epstein–Barr virus) mismatches where the donor is 
positive and the recipient negative, are rare as >95% of the population seroconvert 
by the time they are 20 years of age. Most recipients undergo a B-cell proliferation 
1–3 months post-transplant, but occasionally this can proceed to a post-transplant 
lymphoproliferative disease (PTLD). Monitoring of EBV levels is generally used as 
a marker of over-immunosuppression rather than a way of looking for malignant 
disease. Similarly, with the widespread use of co-trimoxazole as first-line prophy-
laxis, PCP (pneumocystis pneumonia) – also known as PJP (pneumocystis jiroveci 
pneumonia) – is an unusual finding, with rates in solid organ transplant recipients 
reduced from 5 to 15% to 0.3–2.6% [88]. Other respiratory viruses that can have sig-
nificant impact to a transplant recipient includes respiratory syncytial virus (RSV), 
metapneumovirus, influenza/parainfluenza, adenoviruses and rhinovirus. Any of 
these can cause a viral pneumonitis, which can in turn inflict permanent damage to 
the transplanted lungs, either through the inflammatory process of an infection, or 
by triggering acute rejection or chronic allograft dysfunction (CLAD) [89]. Most of 
these infections have no direct treatment, and so management remains supportive 
with the addition of IV methylprednisolone and/or IV immunoglobulin (IVIG) in 
an effort to prevent rejection which can be triggered by these viral infections [89].
Many PwCF are often sensitised to Aspergillus fumigatus and will often be on 
longterm oral antifungals that will need to continue following transplantation. For 
all causes, invasive aspergillosis is the most common cause of all invasive fungal 
infections in lung transplant recipients [90], but it can also be asymptomatic. Often 
however, it will lead to a more pathogenic process, including causing anastomotic 
dehiscence and lung function decline without obvious radiographic changes [91]. 
This process is still not fully understood, which often results in trials of treatment 
to find the most effective. A. fumigatus accounts for 44% of fungal infections in 
the post-lung transplant population, but other common fungal infections post-
transplant include Candida (23%), Scedosporium (20%), Mucorales (3%) and 
Cryptococcus (2%) [92]. Throughout a recipient’s lifetime, it is often difficult to 
tell the difference between rejection and infection as no reliable markers exist. 
Recipients are subjected to frequent invasive investigations (usually bronchoscopy) 
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especially in the early post-transplant period, requiring washings and biopsies to 
differentiate. Patients are encouraged to attend their transplant centres as their local 
referring centre which usually treat patients as having infections rather than con-
sider or have the means to investigate for a diagnosis of rejection. This is especially 
true for PwCF as they are likely to remain positive for their primary pre-transplant 
pathogenic bacteria. It is important to keep in mind that they are also susceptible 
to the same atypical infections as all other lung transplant recipients are, and that 
even if a diagnosis of infection is correct, it may not be caused by the same causative 
organisms as per prior to transplantation.
Part of keeping transplant recipients well includes maintaining appropriate 
prophylactic antibiotic cover. In CF recipients, this often means continuing the 
oral anti-fungals or nebulised antibiotics they were on pre-transplant for a number 
of months at least. If these recipients remains well with no positive microbiology, 
an informed decision to reduce the prophylaxis burden could be considered. All 
recipients are advised to maintain annual vaccines such as the flu vaccine, but other 
vaccines should be discussed with transplant centres as not all vaccines are appro-
priate in the immunosuppressed population.
4.3 Rejection
The first 2 months post-transplant are high risk for acute rejection, as recipient 
lymphocytes encounter donor antibodies for the first time. However, the risk of 
death is low with acute cellular rejection (ACR), and this decreases even further 
with time [93]. Longer term, the risk is of bronchiolitis obliterans syndrome (for 
which ACR is a risk factor) and CLAD. Unlike most other solid organt transplants 
(SOT), lung transplantation has always required a fine balance between adequate 
immunosuppression and the risk of infection. Many patients end up with varying 
individualised immunosuppression based on the number of rejection episodes 
against the rate of infections each person has 28% of surviving lung transplant 
recipients between 2004 and 2015 required treatment for acute rejection in the first 
year post-discharge [3]. Most recipients will require treatment for acute rejection 
in the first year post-transplant, usually in the first 6 months [94]. Treatment is 
usually a short course of high dose IV methylprednisolone (IVMP) for 3–5 days, 
followed by a tapering course over 2–3 weeks. If a patient suffers from recurrent 
bouts of acute rejection and treatment adherence is confirmed, then immunosup-
pression may need to be increased if tolerated renally. Where acute cellular rejection 
is refractory to standard treatment, other modalities of treatment are available. 
RATG has variable success but is still used. Total lymphoid irradiation (TLI) and 
extracorporeal photophoresis are both used with a degree of success in slowing the 
rate of lung function decline, sometimes halting it altogether [95, 96].
Chronic lung allograft dysfunction (CLAD) remains a major barrier to long-
term survival post lung transplantation. Until recently, CLAD and bronchiolitis 
obliterans syndrome (BOS) were used interchangeably. However, the heterogeneity 
of the clinical course of CLAD along with highly variable responses to treatment 
has caused clinicians to review radiology and histology and suggest two distinct 
phenotypes: BOS and restrictive allograft syndrome (RAS) (also known as restric-
tive CLAD (rCLAD)). BOS is characterised by an obstructive picture on pulmonary 
function tests, air trapping on CT imaging, and obliterative bronchiolitis (OB) on 
histology [97]. RAS is characterised by restrictive results on pulmonary function 
tests, pleuro-parenchymal infiltrates on CT and fibro-elastosis on biopsies [98]. It 
is important to differentiate between the two as patients with RAS have an aver-
age expected life expectancy of 6–18 months following diagnosis, compared to 
3–5 years after diagnosis of BOS [97].
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4.4 Malignancy
With improved survival post-transplant, long term complications are increas-
ingly common. Lung transplantation requires higher amounts of immunosuppres-
sion compared with most other solid organ transplants, which increases the risk of 
developing cancer due to impaired anti-tumour immune surveillance and anti-viral 
activity. Malignancies occur in 18% of patients reaching 5 years of survival, and 
28.7% of patients reaching 10 years of survival [99]. Malignancies transmitted from 
the donor are rare due to the surveillance undertaken at the time of donation [100].
PTLD is diagnosed when EBV levels start to rise in association with an abnormal 
white cell count, and is more common in lung transplant recipients than most 
other SOT recipients. It occurs in 2–9% of lung transplant recipients [101, 102]. 
Early cases (within 1 year of transplantation) typically involve the lungs and 
occur in recipients who have not previously been exposed to the virus, whereas 
cases presenting more than 1 year post-transplantation are more likely to involve 
the gastrointestinal (GI) tract [101]. Radiologically, lymphadenopathy and 
pulmonary nodules in the peripheral and basal zones are seen on CT [103]. Post-
transplant immunosuppression impairs T-cell-specific immunity against EBV but 
EBV-negative PTLD has also been recognised. Early-onset PTLD is more likely to 
respond to a reduction in immunosuppression than late-onset as the pathogenesis of 
the latter is less well understood, but this in turn increases the risk of rejection and 
graft failure [104]. As a result, prognosis with late-onset PTLD is worse [102, 105]. 
If reduction in treatment is not the solution, the next option would be rituximab, 
which induces cell death of B-cells via CD20 which is on the surface of these cells.
Non-melanoma skin cancers are the most common skin cancer for SOT recipi-
ents and this is also true in LTx [106, 107]. All lung transplant recipients are advised 
to monitor their skin for any suspicious changes, and regular review by their GP 
or a dermatologist is often recommended. They are also cautioned about time 
spent in the sun and advised to use high factor sun cream liberally. Squamous cell 
carcinomas (SCCs) are 100–200 times more likely to occur post-lung transplant 
compared to the general population [107], and they are usually more aggressive 
with high rates of recurrence [102]. All other forms of skin cancer are more com-
mon than the general population but not to the same extent. The increased risk of 
non-melanoma cancer in all SOT recipients is primarily due to immunosuppression 
which affects the usual cellular pathways that prevent cancerous growths. With LTx 
recipients receiving the highest levels of immunosuppression, it is unsurprising that 
this group of patients have the highest rates of skin cancer. There is also increasing 
evidence that voriconazole increases the risk of SCC [108] and so it is advised to 
reduce the length of treatment time if possible and otherwise switch to an alterna-
tive anti-fungal that appears to have less of an association with cancer.
Treatment is identical to all other skin cancer treatments, aiming for local exci-
sion with complete clearance, but if possible, rates of immunosuppression should 
be reduced to reduce the risk of recurrence or further skin cancers. Radiotherapy is 
an alternative option for those who are high risk for surgery or whose cancers have 
progressed to being inoperable [109]. Monoclonal antibodies have had increasing 
success in the general population, however, these have not been tried to a great 
extent in post-transplant recipients due to concerns over their interaction with 
immunosuppression and risk of graft rejection.
Lung transplant recipients appear to have up to a 5-fold increased risk of lung 
cancer compared to the general population [110], but the risk is primarily related to 
pre-transplant risk factors and so there is a higher incidence in those transplanted 
for COPD or ILD. For PwCF, the risk of developing lung cancer is generally donor-
related risk factors or due to immunosuppression as described earlier. When lung 
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cancer does develop, treatment remains challenging as no treatment has been well-
studied alongside immunosuppression, and outcomes are often poor.
Although all SOT recipients are at increased risk of developing colorectal cancer, 
LTx recipients who have CF have a significantly higher incidence, even within the 
transplant population [111]. This is presumed to be due to the inherent risk of GI 
malignancy in all PwCF compounded with the increased incidence due to immu-
nosuppression. The US-based CF Foundation have recently published Consensus 
guidelines for colorectal cancer screening in PwCF which should be followed post-
transplant also [112]. Further information on colorectal cancer in CF can be found 
in the chapter entitled “Digestive System”.
5. Conclusions
Although lung transplantation in PwCF has achieved results once thought 
impossible, there remains substantial opportunity for progress. Avenues for these 
opportunities include better donor management and organ preservation, improved 
donor allocation systems to offer organs to those most in need who will also benefit 
most, optimization of recipients in terms of physiology, GERD management and 
CFRDM, and prevention of PGD, rejection, and infections. Preoperative pleurode-
sis and lung resections are not contraindications to lung transplantation, however, 
strategic planning with CT imaging and availability of experienced team members 
may reduce complications. While preoperative mechanical ventilation is potentially 
detrimental, patients should be bridged to lung transplantation with ECMO sup-
port, aiming to wake them as soon as is feasible. Bilateral thoracotomy approach is 
superior to the conventional clamshell cosmetically as well as in regards to wound 
complications. Elective use of mechanical circulatory support in LTx for CF is now 
limited to severe secondary pulmonary hypertension or additional cardiac surgery, 
and in the case of hemodynamic instability or inadequate gas exchange on single 
lung ventilation, the operation should be performed under ECMO support.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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